loader from loading.io

Developing Drug Targeting B Cells in Autoimmune Disease of the Kidney IgA Nephropathy with Dr. Marshall Fordyce Vera Therapeutics TRANSCRIPT

Empowered Patient Podcast

Release Date: 05/15/2024

Universal Approach to Cell Therapy Using SNAP-CAR with Dave Mehalick Coeptis Therapeutics TRANSCRIPT show art Universal Approach to Cell Therapy Using SNAP-CAR with Dave Mehalick Coeptis Therapeutics TRANSCRIPT

Empowered Patient Podcast

Dave Mehalick, Chairman, Co-Founder, President, and CEO of Coeptis Therapeutics, focuses on developing cell therapies for oncology and respiratory diseases. They aim to create a universal cell therapy that can be used for various types of cancer and move it from a later line of treatment to a frontline therapy. The company has developed a unique CAR therapy called SNAP-CAR, which utilizes off-the-shelf cells and a targeting mechanism to attack cancer cells at different points, making it difficult for the cells to mutate and evade treatment. Coeptis is conducting clinical trials using its...

info_outline
Universal Approach to Cell Therapy Using SNAP-CAR with Dave Mehalick Coeptis Therapeutics show art Universal Approach to Cell Therapy Using SNAP-CAR with Dave Mehalick Coeptis Therapeutics

Empowered Patient Podcast

Dave Mehalick, Chairman, Co-Founder, President, and CEO of Coeptis Therapeutics, focuses on developing cell therapies for oncology and respiratory diseases. They aim to create a universal cell therapy that can be used for various types of cancer and move it from a later line of treatment to a frontline therapy. The company has developed a unique CAR therapy called SNAP-CAR, which utilizes off-the-shelf cells and a targeting mechanism to attack cancer cells at different points, making it difficult for the cells to mutate and evade treatment. Coeptis is conducting clinical trials using its...

info_outline
Unlocking the Power of CRISPR Technology for Drug Development with Ross Bundy CRISPR QC TRANSCRIPT show art Unlocking the Power of CRISPR Technology for Drug Development with Ross Bundy CRISPR QC TRANSCRIPT

Empowered Patient Podcast

Ross Bundy, President and CEO of CRISPR QC, shines a light on the current state of CRISPR gene editing technology and how the field has advanced rapidly since the discovery of CRISPR's potential to edit the human genome. The focus of CRISPR technology has primarily been on curing rare and genetic diseases, but there is also potential for targeting cancer tumors' resistance to chemotherapy and the development of customized therapies for various indications. The services offered by CRISPR QC include a unique sensor platform and data analytics capability to monitor and control the gene editing...

info_outline
Unlocking the Power of CRISPR Technology for Drug Development with Ross Bundy CRISPR QC show art Unlocking the Power of CRISPR Technology for Drug Development with Ross Bundy CRISPR QC

Empowered Patient Podcast

Ross Bundy, President and CEO of CRISPR QC, shines a light on the current state of CRISPR gene editing technology and how the field has advanced rapidly since the discovery of CRISPR's potential to edit the human genome. The focus of CRISPR technology has primarily been on curing rare and genetic diseases, but there is also potential for targeting cancer tumors' resistance to chemotherapy and the development of customized therapies for various indications. The services offered by CRISPR QC include a unique sensor platform and data analytics capability to monitor and control the gene editing...

info_outline
Therapeutic Cancer Vaccines with Nicolas Poirier OSE Immunotherapeutics TRANSCRIPT show art Therapeutic Cancer Vaccines with Nicolas Poirier OSE Immunotherapeutics TRANSCRIPT

Empowered Patient Podcast

Nicolas Poirier, CEO of OSE Immunotherapeutics, uses immunology and molecular engineering to develop innovative immunotherapies for oncology, inflammation, autoimmune diseases, and organ transplant.  The same immune cells, lymphocytes and macrophages, are involved in both immuno-oncology and immuno-inflammation, and OSE aims to re-educate these cells to recognize and eliminate cancer cells or restore immune tolerance in autoimmune diseases. He also discusses the potential of cancer vaccines in re-educating the immune system to target cancer cells, and the importance of combination...

info_outline
Therapeutic Cancer Vaccines with Nicolas Poirier OSE Immunotherapeutics show art Therapeutic Cancer Vaccines with Nicolas Poirier OSE Immunotherapeutics

Empowered Patient Podcast

Nicolas Poirier, CEO of OSE Immunotherapeutics, uses immunology and molecular engineering to develop innovative immunotherapies for oncology, inflammation, autoimmune diseases, and organ transplant.  The same immune cells, lymphocytes and macrophages, are involved in both immuno-oncology and immuno-inflammation, and OSE aims to re-educate these cells to recognize and eliminate cancer cells or restore immune tolerance in autoimmune diseases. He also discusses the potential of cancer vaccines in re-educating the immune system to target cancer cells, and the importance of combination...

info_outline
Innovative Blood Collection Device Boosts Participation in Decentralized Clinical Trials with Ben Casavant Tasso TRANSCRIPT show art Innovative Blood Collection Device Boosts Participation in Decentralized Clinical Trials with Ben Casavant Tasso TRANSCRIPT

Empowered Patient Podcast

Ben Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection...

info_outline
Innovative Blood Collection Device Boosts Participation in Decentralized Clinical Trials with Ben Casavant Tasso show art Innovative Blood Collection Device Boosts Participation in Decentralized Clinical Trials with Ben Casavant Tasso

Empowered Patient Podcast

Ben Casavant, Co-Founder and CEO of Tasso, focuses on making diagnostics more accessible to patients that allow collection of blood samples at home. Their customers include pharmaceutical companies conducting research and healthcare providers. Using Tasso's technology in decentralized clinical trials allows for easier recruitment, increased patient participation, and more data collection. The simplicity and ease of use of Tasso's blood collection device have resulted in positive patient responses and improved retention rates in clinical trials. They offer liquid and dried blood collection...

info_outline
AI-Powered Device Provides Real-Time Screening  for Early Detection of Heart Failure Symptoms with Chris Darland Peerbridge Health TRANSCRIPT show art AI-Powered Device Provides Real-Time Screening for Early Detection of Heart Failure Symptoms with Chris Darland Peerbridge Health TRANSCRIPT

Empowered Patient Podcast

Chris Darland, President and CEO of Peerbridge Health, discusses technology breakthroughs that enable early, low-cost detection of heart issues with a cardiac monitor that uses AI to analyze heart rhythms over time to detect patterns that may indicate heart failure. The device is based on ECG technology that drives the Holter monitor and delivers a full 12-lead ECG with a volumetric 3D view of the heart. The goal is to reach more patients who may not proactively seek medical attention and provide early intervention and treatment.  Chris explains, " I think the problem with the current...

info_outline
AI-Powered Device Provides Real-Time Screening  for Early Detection of Heart Failure Symptoms with Chris Darland Peerbridge Health show art AI-Powered Device Provides Real-Time Screening for Early Detection of Heart Failure Symptoms with Chris Darland Peerbridge Health

Empowered Patient Podcast

Chris Darland, President and CEO of Peerbridge Health, discusses technology breakthroughs that enable early, low-cost detection of heart issues with a cardiac monitor that uses AI to analyze heart rhythms over time to detect patterns that may indicate heart failure. The device is based on ECG technology that drives the Holter monitor and delivers a full 12-lead ECG with a volumetric 3D view of the heart. The goal is to reach more patients who may not proactively seek medical attention and provide early intervention and treatment.  Chris explains, " I think the problem with the current...

info_outline
 
More Episodes

Dr. Marshall Fordyce, CEO and Founder of Vera Therapeutics, discusses the company's patient-centric approach to developing new medicines for autoimmune diseases. Vera is currently in Phase 3 with a molecule called Atacicept, which targets B cells in autoimmune diseases. They focus on IgA nephropathy, a rare kidney disease, and the third most common cause of kidney failure. A key concern is that declining kidney function is often misdiagnosed and not screened for because the early warning signs are so subtle.

Marshall explains, "Let me give you an example of our lead indication. So, our molecule in development is called atacicept. It targets the immune system in the specific area of B cells, and B cells are the factories of our antibodies, which we need to fight infection over our lifetime. But in patients with autoimmune disease, these B cells are overstimulated, they're overactive, and there are only a few medicines that target B cells with an appropriate balance of safety and efficacy. We had an insight that the science told us that by inhibiting two key factors in the body, BAFF and APRIL, we could normalize that overactivity of B cells and have better outcomes."

"Now traditional drug development may be long and expensive. We were very strategic in picking IgA nephropathy. This is an area that has had very little drug development over the last decade. A few small companies started to become interested in this area, and thankfully, because of patient advocacy, the FDA allowed a surrogate endpoint in Phase 3 trials, which made it more efficient to bring this molecule forward. So, there are now two drugs on the market for the first time in the last three or four years, for two new drugs in IgA nephropathy. They don't target B cells, which is really what's driving this disease. They work downstream, or they're nonspecific."

"What Vera did differently is that we thought that we could actually demonstrate that kidney function, which in these young patients is declining at an alarming rate, if we could demonstrate that kidney function doesn't decline, that would be meaningful. It would be a significant leap. We don't see that happen in "traditional" drug development often, in my view. So, I think what's different here is that we're picking an area where we think we can intervene and, in early-stage development, show a meaningful improvement in outcomes for patients."

#VeraTherapeutics #KidneyDisease #RareDisease #BCells #Immunotherapy #AutoimmuneDiseases #IgANephropathy

veratx.com

Listen to the podcast here

Vera Therapeutics